These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1580304)

  • 21. Nilutamide-induced neutropenia.
    Eaton VS; Blackmore TK
    BJU Int; 2001 Nov; 88(7):801-2. PubMed ID: 11890258
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial.
    Grimaldi C; Bleiberg H; Gay F; Messner M; Rougier P; Kok TC; Cirera L; Cervantes A; De Greve J; Paillot B; Buset M; Nitti D; Sahmoud T; Duez N; Wils J
    J Clin Oncol; 1998 Feb; 16(2):411-7. PubMed ID: 9469323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nilutamide: an antiandrogen for the treatment of prostate cancer.
    Dole EJ; Holdsworth MT
    Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo.
    Brisset JM; Boccon-Gibod L; Botto H; Camey M; Cariou G; Duclos JM; Duval F; Gontiès D; Jorest R; Lamy L
    Prog Clin Biol Res; 1987; 243A():411-22. PubMed ID: 3309973
    [No Abstract]   [Full Text] [Related]  

  • 25. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.
    Decensi AU; Boccardo F; Guarneri D; Positano N; Paoletti MC; Costantini M; Martorana G; Giuliani L
    J Urol; 1991 Aug; 146(2):377-81. PubMed ID: 1856935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen.
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Cusan L; Monfette G; Laberge JG; Emond JP; Raynaud JP; Husson JM; Fazekas AT
    J Steroid Biochem; 1983 Jul; 19(1C):999-1007. PubMed ID: 6411995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma.
    Dupont A; Cusan L; Gomez JL; Koutsilieris M; Suburu R; Emond J; Labrie F
    Br J Urol; 1993 Nov; 72(5 Pt 1):629-34. PubMed ID: 10071551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological and clinical studies of the antiandrogen Anandron.
    Moguilewsky M; Bertagna C; Hucher M
    J Steroid Biochem; 1987; 27(4-6):871-5. PubMed ID: 3320565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and advantages in the use of low doses of Anandron and estrogen combination in the treatment of prostate cancer.
    Rao BR; Geldof AA; van der Wilt CL; de Voogt HJ
    Prostate; 1988; 13(1):69-78. PubMed ID: 3420036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lung caught in Nilutamide treatment.
    Lourenço EP; Nzwalo H; Sampaio MR; Brito H
    BMJ Case Rep; 2016 Sep; 2016():. PubMed ID: 27599808
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluation of efficacy and tolerability of Nilutamide and Buserelin in the treatment of advanced prostate cancer.
    Migliari R; Scarpa RM; Campus G; De Lisa A; Zucca I; D'Atri M; Serra A; Usai E
    Arch Ital Urol Nefrol Androl; 1991 Mar; 63(1):147-53. PubMed ID: 1830407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anandron (nilutamide) combined with orchiectomy in stage D prostate cancer patients. Overview of seven randomized placebo controlled studies.
    Hucher M; de Gery A; Bertagna C
    Cancer; 1993 Dec; 72(12 Suppl):3886-7. PubMed ID: 8252510
    [No Abstract]   [Full Text] [Related]  

  • 33. [Acute depressive syndrome possibly due to nilutamide (Anandron) treatment].
    Maroy B; Pitrou P
    Therapie; 1997; 52(1):79-81. PubMed ID: 9183930
    [No Abstract]   [Full Text] [Related]  

  • 34. [Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer].
    Labrie F; Dupont A; Bélanger A; Lacourcière Y; Monfette JE; Monfette G
    Ann Urol (Paris); 1986; 20(2):98-106. PubMed ID: 2940959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antiandrogen withdrawal syndrome in the hormonal treatment of metastatic prostatic cancer in hormonal escape].
    Barthélémy Y; Colombel M; Gasman D; Patard JJ; Chopin D; Abbou CC
    Prog Urol; 1996 Feb; 6(1):93-7. PubMed ID: 8624534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy with flutamide and [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide in stage C and D prostate cancer: today's therapy of choice--rationale and 5-year clinical experience.
    Labrie F; Dupont A; Cusan L; Bélanger A; Giguère M; Labrie C; Lacourcière Y; Monfette G; Emond J
    Prog Clin Biol Res; 1988; 262():11-63. PubMed ID: 3287388
    [No Abstract]   [Full Text] [Related]  

  • 37. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.
    Harris MG; Coleman SG; Faulds D; Chrisp P
    Drugs Aging; 1993; 3(1):9-25. PubMed ID: 8453188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
    Raina R; Pahalajani G; Agarwal A; Zippe C
    Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
    Kassouf W; Tanguay S; Aprikian AG
    J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer.
    Labrie F; Dupont A; Cusan L; Gomez JL; Diamond P
    Clin Invest Med; 1993 Dec; 16(6):493-8. PubMed ID: 8013154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.